New hope for myeloma: experimental drug combo aims to beat standard care
NCT ID NCT07247097
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial compares two drug combinations for people newly diagnosed with multiple myeloma who are not eligible for or have deferred a stem cell transplant. One group gets the experimental drug elranatamab plus standard medications (lenalidomide, bortezomib, dexamethasone), while the other gets the approved drug daratumumab with the same standard medications. The main goal is to see which combination leads to fewer cancer cells remaining after treatment. About 160 adults will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elranatamab (a bispecific antibody) combined with lenalidomide, bortezomib, and dexamethasone
What this could lead to
If successful, this could offer a new, more effective first-line treatment option for multiple myeloma patients who cannot have a stem cell transplant.
What could go wrong
This is an early phase 2 trial with only 160 participants, so results may not apply to everyone. The new drug combination may cause side effects or not work better than the current standard.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••